Skip to main content
Contact Us
Subscribe
E-Edition
79°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exelixis Inc
(NQ:
EXEL
)
21.39
-0.37 (-1.68%)
Streaming Delayed Price
Updated: 2:11 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exelixis Inc
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Down 76%: Is Cortexyme Stock a Bargain?
October 28, 2021
The biotech's stock took a big hit after its lead product candidate flunked a key clinical trial.
Via
The Motley Fool
Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
October 19, 2021
From
Exelixis, Inc.
Via
Business Wire
EVP And Scientific Strategy Cso Of Exelixis Trades $1.3M In Company Stock
October 18, 2021
Peter Lamb, EVP And Scientific Strategy Cso at Exelixis (NASDAQ:EXEL), made a large buy and sell of company shares on October 15, according to a new SEC filing. What Happened: A...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
More Chinese Trouble
October 14, 2021
A day after the consumer price rise there was another price rise for producer markets.
Via
Talk Markets
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
July 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...
Via
Benzinga
Exposures
COVID-19
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma
October 14, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
October 14, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis's Cabometyx Scores FDA Nod In Differentiated Thyroid Cancer; ESMO Presentation
September 20, 2021
The FDA has approved Exelixis Inc's (NASDAQ: EXEL) Cabometyx (cabozantinib) for thyroid cancer in patients aged 12 years and older. The approval covers...
Via
Benzinga
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
October 07, 2021
Upgrades For State Street Corporation (NYSE:
Via
Benzinga
Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021
September 20, 2021
From
Exelixis, Inc.
Via
Business Wire
A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street; Crude Oil Down 2%
September 20, 2021
Pre-open movers U.S. stock futures traded sharply lower in early pre-market trade after recording losses in the previous session. Investors are awaiting earnings results from...
Via
Benzinga
Exposures
Fossil Fuels
Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021
September 18, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
September 17, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery
September 16, 2021
Exelixis Inc (NASDAQ: EXEL) has announced results demonstrating efficacy benefits of Cabometyx (cabozantinib) in patients with previously untreated advanced renal...
Via
Benzinga
Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021
September 16, 2021
From
Exelixis, Inc.
Via
Business Wire
2 Top Biotech Stocks to Buy Right Now
September 11, 2021
Both have underperformed the market recently. And both are primed for a comeback.
Via
The Motley Fool
Exelixis Statement on the Passing of Two Senior Executives
September 06, 2021
From
Exelixis, Inc.
Via
Business Wire
Is Exelixis Stock a Buy?
September 02, 2021
This biotech stock is down, but it's not out just yet.
Via
The Motley Fool
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September
September 01, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer
August 26, 2021
Exelixis Inc's (NASDAQ: EXEL) collaborating partner Takeda Pharmaceutical Co Ltd (NYSE: TAK) and Ono Pharmaceutical Co Ltd have received...
Via
Benzinga
Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma
August 25, 2021
From
Exelixis, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
August 17, 2021
Gainers Celularity (NASDAQ:CELU) shares rose 7.0% to $7.33 during Tuesday's after-market session. The market value of their outstanding shares is at $904.9...
Via
Benzinga
Exelixis, Invenra Expand Oncology Pact
August 16, 2021
Exelixis Inc (NASDAQ: EXEL) and Invenra have expanded their discovery and licensing collaboration to include 20 additional oncology targets. The augmented...
Via
Benzinga
Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology
August 16, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis, inc (EXEL) Q2 2021 Earnings Call Transcript
August 06, 2021
EXEL earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Recap: Exelixis Q2 Earnings
August 05, 2021
Shares of Exelixis (NASDAQ:EXEL) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 48.00% year over year...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
August 05, 2021
Gainers Sensus Healthcare (NASDAQ:SRTS) ...
Via
Benzinga
Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 05, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis Files US Application For Expanded Use Of Cabometyx In Patients 12+ Years With Thyroid Cancer
August 05, 2021
The FDA has accepted Exelixis Inc's (NASDAQ: EXEL) supplemental marketing application seeking approval for Cabometyx (cabozantinib) for differentiated thyroid...
Via
Benzinga
Exposures
Product Safety
Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
August 05, 2021
From
Exelixis, Inc.
Via
Business Wire
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.